(97 days)
The Delphi Amplifier is intended to be used by or under the direction of a physician for acquisition of EEG signals and to transmit them digitally to a computer. The device is intended for use on humans. The device is intended for use in a clinical environment (e.g., hospital, physician's office, etc.). The device is not intended for use in life support systems.
The Delphi Amplifier has been designed as a mobile recording device for EEG (electroencephalography) signals. It provides access to recorded data over a USB connection to external software over its signal driver interface. The Delphi Amplifier is powered via a USB connection and does not require any additional power source. The Delphi Amplifier supports EEG acquisition and storage by Referential DC input channels, and Parallel trigger input channels. The Delphi Amplifier enables connection of up to 48 referential channels and 8bit trigger input channel. Impedance values can be measured for all referential electrodes as well as the reference. An SDK (Software Development Kit) is available for direct amplifier communication. The device is powered by the USB port connection to a computer. The USB port supports interface to the computer running the SDK.
This document is a 510(k) summary for the Delphi Amplifier, a physiological signal amplifier, specifically for EEG signals. It primarily focuses on demonstrating substantial equivalence to a predicate device (eego amplifiers). This document describes non-clinical bench testing for technical performance and safety, but it does not describe a clinical study involving human patients, human readers, or the establishment of ground truth for a diagnostic AI algorithm. Therefore, many of the requested elements for describing an AI/ML-based diagnostic device's acceptance criteria and study proving its performance cannot be answered from this document.
However, I can extract the information related to the device's technical performance testing:
1. A table of acceptance criteria and the reported device performance
The document does not explicitly present a table of acceptance criteria for each test with numerical performance targets vs. reported values. Instead, it lists the tests performed and states a "Pass" result, indicating that the device met the underlying requirements of these standards.
| Test Category | Test Method Summary | Acceptance Criteria (Implied) | Reported Device Performance |
|---|---|---|---|
| Safety and Essential Performance (Electrical) | Per IEC 80601-2-26 (Electroencephalographs) and IEC 60601-2-26 | Compliance with standard | Pass |
| General Safety and Essential Performance | Per IEC 60601-1 | Compliance with standard | Pass |
| Usability | Per IEC 60601-1-6 | Compliance with standard | Pass |
| Electromagnetic Disturbances | Per IEC 60601-1-2, 60601-2-26 and IEC TR 60601-4-2 | Compliance with standard | Pass |
| System Design Requirement (Data Packet Loss & Long-term Registration) | Stress test assessing data packet loss over 24 hours as well as long term registration test over 24 hours | No errors encountered | No errors encountered. Test passed |
| Reliability Testing | Multiple units tested for reliability over 3160 hours of continuous use. Quality checks performed every 24 hours and main characteristics checked every 1000 hours. | Meets reliability targets | Pass |
| Software and Firmware Testing | Software and firmware testing to ensure device operates per specifications. | Operates per specifications | Pass |
| System Performance Testing (Supplemental to IEC 80601-2-26) | Common-mode rejection ratio, Noise Test and Impedance test | Meets specified parameters | Pass |
2. Sample sized used for the test set and the data provenance (e.g. country of origin of the data, retrospective or prospective)
- Sample Size: The document mentions "Multiple units tested" for reliability. For other tests, specific unit numbers are not provided, but the language implies testing on representative devices. This is not a study on clinical data, but rather on the device hardware/software itself.
- Data Provenance: Not applicable. The testing is bench testing of a physical device, not analysis of patient data.
3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts (e.g. radiologist with 10 years of experience)
- Not applicable. This device is an amplifier for EEG signals, not an AI diagnostic algorithm that requires expert-established ground truth from clinical images or data. The "ground truth" for these tests is defined by the technical specifications and standards (e.g., IEC 60601 series).
4. Adjudication method (e.g. 2+1, 3+1, none) for the test set
- Not applicable. This is not a human assessment study.
5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance
- No. This is not an AI/ML diagnostic device requiring an MRMC study. It is a physiological signal amplifier.
6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done
- "Standalone performance" in this context would refer to the device's technical specifications and performance in measuring/amplifying EEG signals, which is what the bench tests (e.g., Impedance test, Noise test, CMRR) address. The software and firmware testing also falls under this. The document states these tests were passed.
7. The type of ground truth used (expert consensus, pathology, outcomes data, etc)
- The "ground truth" for the performance of this device is defined by the established technical standards (e.g., IEC 60601 series for medical electrical equipment) and the manufacturer's own design specifications (e.g., "no errors encountered" for data packet loss, "operates per specifications" for software/firmware). It's a hardware/software performance "ground truth" rather than a clinical diagnostic "ground truth."
8. The sample size for the training set
- Not applicable. This is a hardware device (amplifier) with associated software/firmware, not a machine learning model that requires a training set of data.
9. How the ground truth for the training set was established
- Not applicable. As above, this is not an ML model.
{0}------------------------------------------------
March 12, 2025
Image /page/0/Picture/1 description: The image shows the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which consists of the letters "FDA" in a blue square, followed by the words "U.S. FOOD & DRUG ADMINISTRATION" in blue text.
QuantalX Neuroscience % Bosmat Friedman-Cox Regulatory Consultant ProMedoss, Inc. 6026 Beech Cove Ln. Charlotte, North Carolina 28269
Re: K243746
Trade/Device Name: Delphi Amplifier Regulation Number: 21 CFR 882.1835 Regulation Name: Physiological Signal Amplifier Regulatory Class: Class II Product Code: GWL Dated: December 5, 2024 Received: February 14, 2025
Dear Bosmat Friedman-Cox:
We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device"
{1}------------------------------------------------
(https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download).
Your device is also subject to, among other requirements, the Quality System (QS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30. Design controls; 21 CFR 820.90. Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review, the OS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181).
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.
All medical devices, including Class I and unclassified devices and combination product device constituent parts are required to be in compliance with the final Unique Device Identification System rule ("UDI Rue"). The UDI Rule requires, among other things, that a device bear a unique device identifier (UDI) on its label and package (21 CFR 801.20(a)) unless an exception or alternative applies (21 CFR 801.20(b)) and that the dates on the device label be formatted in accordance with 21 CFR 801.18. The UDI Rule (21 CFR 830.300(a) and 830.320(b)) also requires that certain information be submitted to the Global Unique Device Identification Database (GUDID) (21 CFR Part 830 Subpart E). For additional information on these requirements, please see the UDI System webpage at https://www.fda.gov/medical-devices/device-advicecomprehensive-regulatory-assistance/unique-device-identification-system-udi-system.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
{2}------------------------------------------------
Sincerely,
Image /page/2/Picture/3 description: The image shows the name "Patrick Antkowiak -S" in black text. To the left of the name is a light blue FDA logo. The text is aligned to the left and the logo is slightly transparent.
for Jay Gupta Assistant Director DHT5A: Division of Neurosurgical, Neurointerventional, and Neurodiagnostic Devices OHT5: Office of Neurological and Physical Medicine Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health
Enclosure
{3}------------------------------------------------
Indications for Use
510(k) Number (if known) K243746
Device Name Delphi Amplifier
Indications for Use (Describe)
The Delphi Amplifier is intended to be used by or under the direction of a physician of EEG signals and to transmit them digitally to a computer. The device is intended for use on humans. The device is intended for use in a clinical environment (e.g., hospital, physician's office, etc.). The device is not intended for use in life support systems.
| Type of Use (Select one or both, as applicable) |
|---|
| Prescription Use (Part 21 CFR 801 Subpart D) |
| Over-The-Counter Use (21 CFR 801 Subpart C) |
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
{4}------------------------------------------------
Image /page/4/Picture/0 description: The image shows the logo for Quantalx Neuroscience. The word "Quantalx" is written in a bold, sans-serif font. Below the word "Quantalx" is the word "Neuroscience" written in a smaller, purple font. The word "Neuroscience" is surrounded by two purple dots.
Traditional 510(k)
510(k) Summary
510(k) Summary [Traditional 510(k)] Delphi Amplifier - K243746
SUBMITTER 1
Applicant's Name:
QuantalX Neroscience 1 Hatachana St. Kfar-Saba Israel
Primary Contact:
Bosmat Friedman Regulatory Affairs Consultant 6026 Beech Cove Ln. Charlotte, NC 28269 Phone: 980-308-1636 bosmat.f(@promedoss.com
Date Prepared: February 14, 2025
Trade Name:
Delphi Amplifier
| Classification Code: | Device: Amplifier, Physiological Signal |
|---|---|
| Product Code: GWL | |
| Regulation No: 882.1835 | |
| Class: 2 | |
| Review Panel: Neurology |
2 PREDICATE DEVICE
Primary Predicate:
- eego amplifiers. Product code: GWL, cleared under: K172312. .
3 DEVICE DESCRIPTION
The Delphi Amplifier has been designed as a mobile recording device for EEG (electroencephalography) signals. It provides access to recorded data over a USB connection to external software over its signal driver interface. The Delphi Amplifier is powered via a USB connection and does not require any additional power source. The Delphi Amplifier supports EEG acquisition and storage by Referential DC input channels, and Parallel trigger input channels.
The Delphi Amplifier enables connection of up to 48 referential channels and 8bit trigger input channel. Impedance values can be measured for all referential electrodes as well as the reference. An SDK (Software Development Kit) is available for direct amplifier communication.
{5}------------------------------------------------
| Quantalx• Neuroscience • | Delphi Amplifier | |
|---|---|---|
| Traditional 510(k) | 510(k) Summary |
The device is powered by the USB port connection to a computer. The USB port supports interface to the computer running the SDK.
INDICATIONS FOR USE ব
The Delphi Amplifier is intended to be used by or under the direction of a physician for acquisition of EEG signals and to transmit them digitally to a computer. The device is intended for use on humans. The device is intended for use in a clinical environment (e.g., hospital, physician's office, etc.). The device is not intended for use in life support systems.
റ SUBSTANTIAL EQUIVALENCE
The Delphi Amplifier is substantially equivalent to the predicate device based on the following:
6 INTENDED USE
The intended use of the proposed device is the same as that of the cleared device.
7 TECHNOLOGY
The Delphi Amplifier device has similar overall technological characteristics as the predicate eego amplifier cleared under K172312. Both devices are comprised of an amplifier unit provided with the Software Development Kit (SDK) and accompanying user manuals for both components. Both devices are prescription devices intended to be used in a clinical environment by connecting to a PC and FDA cleared electrodes to acquire EEG signals.
| Subject Device | Predicate Device | Comparison | |
|---|---|---|---|
| Attribute | Delphi Amplifier | Eego Amplifier | |
| 510(k) Number | NA | K172312 | -- |
| Classification | GWL | GWL | Same |
| Regulation Number | 882.1835 | 882. 1835 | Same |
| Intended Use | Used to electrically amplify signals derived from electroencephalogram | Used to electrically amplify signals derived from electroencephalogram. | Same |
| Indications for use | The Delphi Amplifier is intended to be used by or under the direction of a physician for acquisition of EEG signals and to transmit them digitally to a computer. The device is intended for use on humans. The device is intended for use in a clinical environment (e.g., hospital, physician's office, etc.). The device is not intended for use in life support systems. | The eego amplifier is intended to be used by or under the direction of a physician for acquisition of EEG signals and to transmit them digitally to a computer. The device is intended for use on humans. The device is intended for use in a clinical environment (e.g., hospital, physician's office, etc). The device is not intended for use in life support systems. | Same |
| Type of use | Prescription Use | Prescription Use | Same |
| Modes of Operation | Connected to a PC and FDA cleared electrodes to acquire EEG signals | Connected to a PC and FDA cleared electrodes to acquire EEG signals | Same |
| Use Environment | Clinical environment (hospital, clinic, physician's office, etc.) | Clinical environment (hospital, clinic, physician's office, etc.) | Same |
| Filter | Low pass filtering in amplifier | Low pass filtering in amplifier | Same |
| Sampling rate | 125, 250, 500, 1000, 2000 Hz @ all channels5000 Hz @ 24 FEG monopolar or | EE-2XX Series:Up to 16384 Hz Set through the user interface of the Software Development | Equivalent; Delphi Amplifier can be configured to higher |
{6}------------------------------------------------
Traditional 510(k)
510(k) Summary
| Attribute | Subject Device | Predicate Device | Comparison |
|---|---|---|---|
| Delphi Amplifier | Eego Amplifier | ||
| bipolar channels10000 Hz @ 16 EEG monopolar orbipolar channels50000 Hz @ 4 EEG monopolar orbipolar channelsset through SDK | Kit (SDK) softwareEE-4XX Series: Up to 2048 Hz | sampling rate inreduced montage. | |
| Amplifier CMRR(referential) | >100 dB | >100 dB | Same |
| Amplifier InputChannels | Up to 48 | Up to 64 | Similar; whileDelphi has less inputchannels, there arevarious FDA cleareddevices with 16-128input channels. |
| Amplifier inputimpedance(referential) | >108 Ohm | >109 Ohm | Equivalent for lowimpedance ofphysiological signalinputs. |
| Amplifier power | USB from Computer | EE-2XX Series: Rechargeableintegrated batteryEE-4XX Series: USB from Computer | Same as EE-4xxmodel |
| Resolution andinput stage | 24-bit, true DC input for all channels | 24-bit, true DC input for all channels,one A/D converter per channel | Similar |
| Input noise(referential) | < 0.9 uV p-p (lowest sampling rate andsignal range) | <1.0 µVRMS (lowest sampling rate andsignal range) | Equivalent |
| Amplifierreferential DCinput channels | Yes | Yes | Equivalent |
| Amplifier triggerinput | Yes | Yes | Equivalent |
| Amplifier triggerinput channel | Yes | Yes | Equivalent |
| Amplifier USBinterface | Yes | Yes | Equivalent |
| PC interface | SDK (API) | SDK (API) | Equivalent |
8 DISCUSSION
Based on the comparison presented in our submission, the Delphi Amplifier shares the same indications for use as its predicate, as both are intended to be used by or under the direction of a physician for acquisition of EEG signals and to transmit them digitally to a computer. Additionally, while some technological differences do exist between the subject device and its predicate, testing have demonstrated that the device is substantially equivalent to its predicate and that the technological differences do not raise new safety and effectiveness concerns and support the company's substantial equivalency claim.
9 PERFORMANCE DATA
The Amplifier underwent successful nonclinical bench tests to establish substantially equivalent performance. The tests are summarized below:
{7}------------------------------------------------
Traditional 510(k)
510(k) Summary
| Test | Test Method Summary | Results |
|---|---|---|
| Particular requirements for the basic safetyand essential performance ofelectroencephalographs | Per IEC 80601-2-26 and IEC 60601-2-26 | Pass |
| Medical electrical equipment - Part 1:General requirements for basic safety andessential performance | Per IEC 60601-1 | Pass |
| Medical electrical equipment - Part 1-6:General requirements for basic safety andessential performance - Collateral standard:Usability | Per IEC 60601-1-6 | Pass |
| Medical electrical equipment: Part 1-2General requirements for basic safety andessential performance. Collateral Standard:electromagnetic disturbances- Requirementsand tests. | Per IEC 60601-1-2, 60601-2-26 andIEC TR 60601-4-2 | Pass |
| System Design Requirement | Stress test assessing data packet lossover 24 hours as well as long termregistration test over 24 hours | No errorsencountered. Testpassed |
| Reliability testing | Multiple units tested for reliabilityover 3160 hours of continuous use.Quality checks performed every 24hours and main characteristics checkedevery 1000 hours. | Pass |
| Delphi amplifier software and firmwaretesting | Software and firmware testing toensure device operates perspecifications. | Pass |
| System performance testing | Supplemental testing to IEC 80601-2-26 which included Common-moderejection ratio, Noise Test andImpedance test | Pass |
The results of the bench testing support the safety profile of the device and demonstrate that the device functions as intended.
10 CONCLUSION
The Delphi Amplifier has similar intended use, technological characteristics, and principles of operation as the predicate. Any differences between the subject and predicate device were evaluated through design verification and validation testing which demonstrated device performance and safety, and do not raise any new questions of safety and effectiveness. Based on the information submitted in this 510(k), the Delphi Amplifier is substantially equivalent to the predicate eego Amplifiers.
§ 882.1835 Physiological signal amplifier.
(a)
Identification. A physiological signal amplifier is a general purpose device used to electrically amplify signals derived from various physiological sources (e.g., the electroencephalogram).(b)
Classification. Class II (performance standards).